Jefferies downgraded Reneo Pharmaceuticals to Hold from Buy with a price target of $1.80, down from $17. The company’s’ sole asset mavodelpar failed to show clinical benefits distinguishable from placebo in a rare mitochondrial disease, resulting in program suspension and a 70% workforce reduction, the analyst tells investors in a research note. The firm says Reneo will provide details on its next step in January.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RPHM:
- Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Block upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- Reneo Pharmaceuticals initiated with an Outperform at William Blair
- Reneo Pharmaceuticals files $300M mixed securities shelf
- Reneo Pharmaceuticals reports Q3 EPS (57c), consensus (57c)